Table of Contents
Surgical Robot Market Overview
Surgical robot companies provide enhanced precision and efficiency in minimally invasive procedures. They feature robotic arms with specialized tools, a control console for the surgeon, and often an endoscope for real-time imaging.
Benefits include greater precision, less invasiveness, and better visualization, resulting in faster recovery and reduced pain. Used in fields such as urology, gynecology, and cardiothoracic surgery, these robots reduce surgeon fatigue and provide high-definition 3D views.
However, high costs, specialized training needs, and technical challenges persist. Future advancements may include AI integration and increased accessibility.
Market Drivers
The global surgical robot market is expanding due to several key factors. Technological advancements, such as enhanced precision and miniaturization, drive growth.
The rising demand for minimally invasive procedures and the increasing incidence of chronic diseases further boost adoption.
The growing geriatric population and the potential for improved surgical outcomes also contribute to market expansion.
Additionally, the integration of AI with robotic systems enhances their capabilities and expands healthcare infrastructure. Along with significant investments in the field, supports the market’s growth.
Market Size
The global surgical robots market is projected to reach approximately USD 19.4 billion by 2032. Up from USD 7.8 billion in 2022, with a CAGR of 9.80% from 2023 to 2032.
List of Major Companies
These are the top companies operating in the Surgical Robot Market:
- Intuitive-Surgical
- Medtronic
- Stryker
- Johnson-n-Johnson
- Zimmer-Biomet
- Smith-n-Nephew
- Renishaw
- Omron
- CMR-Surgical
- Siemens
Intuitive-Surgical
Company Overview
| Establishment Year | 1995 |
| Headquarter | Sunnyvale, California, U.S. |
| Key Management | Gary S. Guthart (CEO) |
| Revenue (US$ Bn) | $ 7.1 B (2023) |
| Headcount | ~ 13,676 (2023) |
| Website | http://intuitive.com/ |
About Intuitive Surgical
Intuitive Surgical, Inc., a leader in surgical robotics, has recently advanced its market position by enhancing product offerings and expanding its footprint through strategic acquisitions and regulatory progress.
The integration of Luna Innovations’ shape-sensing technology into the da Vinci robotic systems has improved surgical precision with real-time measurements.
The company has also achieved significant regulatory milestones, including FDA 510(k) clearances for the Ion Endoluminal System and approval for the da Vinci 5 robotic system.
Additionally, recent board appointments and partnerships reflect a strategic focus on technological innovation and market expansion, underscoring Intuitive Surgical’s commitment to maintaining its leadership in the surgical robotics sector.
Geographical Presence
Intuitive Surgical operates extensively across the globe, with a notable presence in North America, Europe, Asia-Pacific, Latin America, and the Middle East.
Headquartered in Sunnyvale, California, the company has a strong foothold in the U.S. and Canada. In Europe, it is active in key markets, including the UK, Germany, and France.
The company is expanding in the Asia-Pacific region, with significant operations in China, Japan, South Korea, and India. In Latin America, Brazil and Mexico are prominent markets, while in the Middle East, the focus includes the UAE and Saudi Arabia.
Intuitive Surgical’s global strategy involves regional offices, partnerships with healthcare institutions, and participation in industry events to enhance its market presence and adapt to diverse healthcare needs.
Recent Developments
- In March 2024, Intuitive Surgical partnered with FluoGuide to develop FG001, a new technology aimed at improving tumor imaging and assessing surgical margins for head and neck cancer.
- In March 2024, Intuitive Surgical gained FDA approval for its fifth-generation multiport robotic system, the da Vinci 5.
Medtronic
Company Overview
| Establishment Year | 1949 |
| Headquarter | Dublin, Ireland |
| Key Management | Geoff Martha (CEO) |
| Revenue (US$ Bn) | $ 32.3 B (2024) |
| Headcount | ~ 95,000 (2024) |
| Website | https://www.medtronic.com/ |
About Medtronic
Medtronic has been actively enhancing its presence in the surgical robot companies/sector through strategic acquisitions, product innovations, and market expansion initiatives.
The company’s recent acquisition of Affera, a firm specializing in cardiac mapping and navigation, highlights Medtronic’s focus on integrating cutting-edge technologies into its portfolio to broaden its diagnostic and therapeutic offerings.
Furthermore, Medtronic has continued to demonstrate strong performance despite challenges like the COVID-19 pandemic, which has impacted procedure volumes.
Their ability to launch new products and maintain revenue growth during these times attests to their robust operational framework and commitment to innovation.
This strategic approach not only strengthens Medtronic’s market position but also ensures it remains at the forefront of technological advancements in the surgical robots sector.
Geographical Presence
Medtronic plc has a broad global presence, with significant operations across major regions. In North America, the company has a substantial market share in the U.S. and Canada, supported by numerous facilities.
In Europe, the company is well-established across Western, Northern, Southern, and Eastern Europe, as well as in the Middle East and Africa, where it addresses diverse healthcare needs.
In the Asia-Pacific region, Medtronic is expanding rapidly in China, India, Japan, and Southeast Asia while maintaining a strong presence in Australia and New Zealand.
This extensive geographical footprint enables Medtronic to leverage market opportunities and meet varied healthcare demands worldwide.
Recent Developments
- In September 2024, Medtronic opened a Robotics Experience Studio in Southeast Asia.
- In August 2024, Medtronic sold its Paceart Optima system to PaceMate, a Florida-based company.
Stryker
Company Overview
| Establishment Year | 1941 |
| Headquarter | Michigan, U.S. |
| Key Management | Kevin A. Lobo (CEO) |
| Revenue (US$ Bn) | $ 20.5 B (2023) |
| Headcount | ~ 52,000 (2023) |
| Website | http://stryker.com/ |
About Stryker
Stryker Corporation has recently fortified its position in the surgical robot companies/sector through strategic acquisitions and the introduction of advanced medical technologies.
Notably, the acquisition of MOLLI Surgical in 2024 has expanded its capabilities in breast cancer care with innovative, wire-free soft tissue localization technology, enhancing surgical precision and workflow efficiency.
Additionally, the 2022 acquisition of Vocera Communications has broadened Stryker’s digital healthcare and care coordination offerings, aiming to improve patient outcomes and streamline care processes.
These developments reflect Stryker’s ongoing commitment to integrating cutting-edge technologies and expanding its product portfolio better to serve healthcare providers and patients in complex surgical environments.
Geographical Presence
Stryker Corporation, a leading global medical technology company, boasts a substantial geographical presence across multiple regions.
In North America, it operates extensively with facilities in the United States and Canada. In Europe, Stryker has a strong footprint in Western, Southern, Northern, and Eastern Europe.
In the Asia-Pacific region, it maintains a significant presence in China, Japan, India, and Australia/New Zealand. In Latin America, the company has notable operations in Brazil and Mexico, with expanding activities in other countries.
Its presence extends to the Middle East and Africa, including key markets such as the UAE, Saudi Arabia, and South Africa. This widespread geographical reach supports Stryker’s global market access and growth strategy.
Recent Development
- In July 2024, Stryker acquired MOLLI Surgical, a company specializing in wire-free technology for breast-conserving surgery.
- In February 2022, Stryker acquired Vocera Communications, a leader in digital care coordination and communication.
Johnson-n-Johnson
Company Overview
| Establishment Year | 1886 |
| Headquarter | New Brunswick, New Jersey, U.S. |
| Key Management | Joaquin Duato (CEO) |
| Revenue (US$ Bn) | $ 85.1 B (2023) |
| Headcount | ~ 134,400 (2023) |
| Website | https://www.jnj.com/ |
About Johnson & Johnson
Johnson & Johnson has strengthened its position in surgical robotics through key acquisitions and investments in cutting-edge technologies.
Recent moves include acquiring Shockwave Medical to enhance its cardiovascular intervention capabilities with intravascular lithotripsy technology and Auris Health to expand its digital surgery portfolio with the Monarch Platform.
The company also acquired Ambrx Biopharma to advance its oncology pipeline with antibody-drug conjugates and V-Wave to introduce novel treatments for heart failure with the Ventura® Interatrial Shunt device.
These strategic acquisitions underscore Johnson & Johnson’s commitment to advancing medical technology and improving patient outcomes across various fields.
Geographical Presence
Johnson & Johnson maintains a robust global presence across various regions. In North America, its operations are concentrated in the U.S. and Canada, with a strong focus on R&D and manufacturing.
In Europe, the company has significant activities in both Western and Eastern regions, including Germany, France, the UK, and Russia.
Asia-Pacific markets are pivotal, with major operations in China, India, Japan, and Southeast Asia. Latin America sees substantial activity in Brazil and Mexico, while in the Middle East and Africa, South Africa and the Middle East serve as key hubs.
This extensive geographical footprint supports Johnson & Johnson’s leadership in the global healthcare sector, enabling it to address diverse market needs effectively.
Recent Development
- In August 2024, Johnson & Johnson acquired V-Wave Ltd., a private firm specializing in innovative heart failure treatments.
- In March 2024, Johnson & Johnson acquired Ambrx Biopharma, a company specializing in advanced antibody-drug conjugates (ADCs).
Zimmer-Biomet
Company Overview
| Establishment Year | 1927 |
| Headquarter | Warsaw, Indiana, U.S. |
| Key Management | Ivan Tornos (CEO) |
| Revenue (US$ Bn) | $ 7.3 B (2023) |
| Headcount | ~ 18,000 (2023) |
| Website | http://zimmerbiomet.com/ |
About Zimmer Biomet
Zimmer Biomet has made significant strides in the surgical robot companies/sector, notably through its recent acquisition of OrthoGrid Systems.
This acquisition enriches Zimmer Biomet’s portfolio with advanced AI-driven surgical guidance systems, particularly for hip replacement surgeries, enhancing intraoperative accuracy and efficiency without the need for preoperative CT scans.
The integration of OrthoGrid’s fluoroscopy-based technology and its robust patent collection supports Zimmer Biomet’s strategic expansion within the orthopedic surgical market, focusing on improving surgical outcomes and operational efficiencies.
Geographical Presence
Zimmer Biomet Holdings, Inc., a leading global medical device company, maintains a robust geographical presence. In North America, it operates extensively, with its headquarters in Warsaw, Indiana, and strong networks across the United States and Canada.
In the EMEA region, Zimmer Biomet has a significant footprint in Western and Eastern Europe and the Middle East, as well as a growing presence in Africa.
The Asia-Pacific region includes key markets such as China, India, Japan, and Australia. In Latin America, the company focuses on Brazil, Mexico, and other emerging markets.
Strategic investments in distribution networks and local partnerships enhance its ability to meet regional demands and expand its market reach.
Recent Developments
- In August 2024, Zimmer Biomet acquired OrthoGrid Systems, Inc., a medical technology company.
- In August 2024, Zimmer Biomet acquired OrthoGrid Systems, which specializes in AI-powered surgical guidance for hip replacements.
Smith-n-Nephew
Company Overview
| Establishment Year | 1865 |
| Headquarter | Watford, England, UK |
| Key Management | Rupert Soames (Chairman) |
| Revenue (US$ Bn) | $ 5.5 Billion (2023) |
| Headcount | ~ 20,000 (2023) |
| Website | https://www.smith-nephew.com/ |
About Smith & Nephew
Smith & Nephew has recently expanded its portfolio in the surgical robot companies/sector with significant developments in sports medicine, particularly through the acquisition of CartiHeal.
This acquisition introduces the Agili-C cartilage regeneration technology into their offerings, aiming to set a new standard in the treatment of knee joint surface lesions.
The Agili-C device, which has received both Breakthrough Device designation and Premarket Approval from the FDA, demonstrates Smith & Nephew’s commitment to advancing innovative solutions in sports medicine.
Additionally, the acquisition of Engage Surgical strengthens Smith & Nephew’s position in the cementless partial knee systems market, reflecting the company’s strategy to enhance its capabilities in high-growth sectors within orthopedics.
These strategic moves are expected to significantly boost Smith & Nephew’s market presence by enhancing surgical outcomes and expanding their technology-driven product lines.
Geographical Presence
Smith & Nephew plc, a global medical technology company, operates extensively across various regions. Its North American presence includes major facilities in the United States and Canada.
In Europe, the company has significant operations in the United Kingdom, Germany, France, Italy, and Spain. The Asia-Pacific region is served through key markets in Australia, New Zealand, China, and Japan.
In Latin America, Smith & Nephew is active in Brazil and Mexico, while in the Middle East and Africa, it maintains a strategic presence in South Africa and GCC countries.
This broad geographical reach supports the company’s diverse product offerings and adapts to local healthcare needs and market conditions.
Recent Developments
- In June 2024, Smith & Nephew introduced its new CORIOGRAPH Preoperative Planning and Modeling Services.
- In January 2024, Smith & Nephew acquired CartiHeal, known for its Agili-C technology, which advances cartilage regeneration in the knee.
Renishaw
Company Overview
| Establishment Year | 1973 |
| Headquarter | Wotton-under-Edge, England, UK |
| Key Management | Sir David McMurtry (Executive Chairman) |
| Revenue (US$ Bn) | $ 848.7 Million (2022) |
| Headcount | ~ 5,136 (2023) |
| Website | https://www.renishaw.com/ |
About Renishaw
Renishaw has made strides in the healthcare sector, particularly in enhancing medical procedures and manufacturing custom medical devices.
They’ve established a dedicated Healthcare Centre of Excellence in South Wales, which focuses on producing custom medical devices and serves as a training hub for life sciences, reflecting Renishaw’s commitment to advancing healthcare technologies.
In the realm of surgical robotics, Renishaw’s contributions are notable, especially in neurosurgery. Their systems are designed to support complex procedures like deep brain stimulation and stereoelectroencephalography, aiming to improve surgical outcomes and reduce procedure times.
The company leverages its expertise in precision engineering and additive manufacturing to create specialized medical devices, such as patient-specific implants and surgical instruments, underscoring its role in driving forward medical and technological innovations in surgery.
Geographical Presence
Renishaw plc, headquartered in Wotton-under-Edge, UK, operates globally and has a strong presence across multiple regions.
In Europe, it has key facilities in Germany, France, Italy, Spain, and Switzerland, as well as other European countries through partners.
In North America, Renishaw has significant operations in the United States and Canada. The company maintains a robust presence in the Asia-Pacific region, with offices in China, Japan, India, South Korea, and Australia.
South America is served through a subsidiary in Brazil, while regional offices in the UAE and South Africa support the Middle East and Africa. This extensive geographical reach allows Renishaw to serve diverse markets worldwide effectively.
Recent Developments
- In July 2024, Renishaw launched two new technology centers in Chennai, India, and Nagoya, Japan.
- In May 2024, Renishaw opened a facility in Sao Paulo, Brazil.
Omron
Company Overview
| Establishment Year | 1933 |
| Headquarter | Kyoto, Japan |
| Key Management | Junta Tsujinaga (CEO) |
| Revenue (US$ Bn) | $ 5.7 Billion (2023) |
| Headcount | ~ 28,450 (2023) |
| Website | http://www.omron.com/ |
About Omron
Omron Corporation has significantly enhanced its capabilities in the surgical robot companies/sector, especially following its strategic acquisition of Adept Technology.
This move, completed to bolster Omron’s offerings in automation and robotics, aimed to enhance manufacturing processes across various industries, including automotive and packaging, through advanced robotic solutions.
Notably, Omron introduced the world’s first “Robotic Integrated Controller”, designed to synchronize automation technology across all equipment, which marks a substantial leap in facilitating more efficient, accurate, and flexible production systems.
This development is aligned with Omron’s ongoing commitment to innovation in industrial automation, leveraging robotics to improve production speed and operational efficiency.
Geographical Presence
Omron Corporation, headquartered in Kyoto, Japan, maintains a robust global presence with significant operations across multiple regions.
In North America, the company has major facilities in the U.S. and Canada, including key offices in Chicago and Toronto. In Europe, Omron is well-represented in the U.K., Germany, and France.
The Asia-Pacific region features extensive operations in China, India, and South Korea. In Latin America, Brazil and Mexico serve as major hubs, while offices in Dubai and Johannesburg support the Middle East and Africa.
This expansive geographical footprint enables Omron to deliver tailored solutions and localized support across various markets.
Recent Development
- In August 2024, Omron partnered with Neura Robotics to improve manufacturing through AI-driven cognitive robots.
- In June 2024, Omron teamed up with Digimarc to combine machine vision with digital watermarks, improving production processes across multiple industries.
CMR-Surgical
Company Overview
| Establishment Year | 2014 |
| Headquarter | Cambridge, United Kingdom |
| Key Management | Luke Hares (Founder) |
| Revenue (US$ Bn) | $ 32.6 Million (2021) |
| Headcount | ~ 647 (2021) |
| Website | https://cmrsurgical.com/ |
About CMR Surgical
CMR Surgical has made notable progress in the surgical robotics field with its Versius Surgical Robotic System, recently marking over 20,000 surgeries across various specialties such as urology, gynecology, and thoracic surgery.
The system’s adaptable design facilitates its integration into diverse hospital settings, boosting its adoption. In the final quarter of 2023, CMR Surgical achieved record installations of Versius, reflecting its increasing global acceptance.
Additionally, the company launched vLimeLite, a new imaging technology that enhances visualization with Versius.
Looking ahead to 2024, CMR Surgical plans to introduce further technological innovations to expand the capabilities of the Versius system, reinforcing its commitment to advancing robotic-assisted surgeries worldwide.
Geographical Presence
CMR Surgical Ltd., renowned for its Versius® robotic surgical system, has established a significant global presence. In Europe, the company has a strong foothold in the UK, Germany, France, Spain, and Italy.
In North America, CMR is making strides in the U.S. and Canada. The Asia-Pacific region, including India, China, and Australia, is also a key focus, with ongoing efforts to integrate Versius® systems.
Additionally, CMR Surgical is expanding into the Middle East and Africa, with notable initiatives in the UAE and South Africa.
This strategic expansion reflects CMR Surgical’s commitment to addressing the global demand for advanced surgical technologies through local partnerships and targeted market entry.
Recent Developments
- In March 2024, CMR announced that over 20,000 surgeries had been performed with the Versius system, as the company collaborates globally with hospitals and surgeons to expand access to minimally invasive surgery.
- In February 2024, CMR introduced vLimeLite, an integrated fluorescence imaging system for visualizing Indocyanine Green (ICG), providing surgeons with improved visualization when needed.
Siemens
Company Overview
| Establishment Year | 1847 |
| Headquarter | Munich, Germany |
| Key Management | Roland Busch (CEO) |
| Revenue (US$ Bn) | $ 81.8 Billion (2022) |
| Headcount | ~ 320,000 (2023) |
| Website | https://www.siemens.com/ |
About Siemens
Siemens AG has been proactively enhancing its capabilities in the surgical robotics sector, focusing on developing and integrating advanced technologies into its healthcare offerings.
In 2023, Siemens Healthineers expanded its partnership with KUKA, planning to supply 300 robots for the ARTIS pheno angiography system, which is pivotal in cardiological, interventional, and other surgical disciplines.
This system is noted for its versatility in hybrid operating rooms, enhancing the precision of medical interventions.
Additionally, Siemens has launched several innovative products, such as the Acuson Maple ultrasound system, which features AI-powered functionalities to aid in diverse clinical settings, and the Somatom Pro. Pulse is a Dual Source CT scanner designed for enhanced accessibility in various medical environments.
These developments underscore Siemens’ commitment to advancing medical technology through strategic partnerships, innovative product launches, and a focus on sustainability and efficiency in medical imaging and diagnostics.
Geographical Presence
Siemens AG, a leading global electronics and electrical engineering company, boasts a diverse geographical presence across major regions. In Europe, key operations are centered in Germany, the UK, France, Italy, and Spain, focusing on industrial automation and energy.
In North America, Siemens has substantial facilities in the United States and Canada, engaging in sectors like manufacturing and healthcare.
Latin America sees significant activity in Brazil and Mexico, while in Asia-Pacific, the company has a major footprint in China, India, and Japan, emphasizing automation and digital industries.
Additionally, Siemens operates in the Middle East and Africa, with a notable presence in the UAE and South Africa, focusing on infrastructure and energy solutions.
This extensive global reach reflects Siemens AG’s strategic emphasis on innovation and market responsiveness.
Recent Development
- In September 2024, Siemens entered into an agreement with Summit Ridge Energy for domestic content inverters.
- In August 2024, Siemens and TOBEA entered into a partnership to launch the SEATRAC system.
Discuss Your Needs With Our Analyst
Please share your requirements with more details so our analyst can check if they can solve your problem(s)
